HDM1005
Sources
registry, as of 2025-12-12Stale
https://clinicaltrials.gov/study/NCT07279194
Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 825. Conditions Obesity & Overweight. This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy andsafety of the HDM1005 in patients with obesity or overweight. Eligible participants will be screened and randomized to different dose group of HDM1005 or the placebo group at a rati
ClinicalTrials.gov NCT07279194 protocol and results modules
registry, as of 2026-08-31Stale
https://clinicaltrials.gov/study/NCT07794397
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 200. Conditions Obstructive Sleep Apnea (OSA) and Obesity. This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy and safety of the HDM1005 in patients with obstructive sleep apnea (OSA) and obesity receiving positive airway pressure (PAP) therapy. Eligible participants will be screened and random
ClinicalTrials.gov NCT07794397 protocol and results modules
registry, as of 2026-08-26Stale
https://clinicaltrials.gov/study/NCT07787260
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 200. Conditions Obstructive Sleep Apnea (OSA) and Obesity. This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy and safety of the HDM1005 in patients with obstructive sleep apnea (OSA) and obesity not receiving positive airway pressure (PAP) therapy. Eligible participants will be screened and ra
ClinicalTrials.gov NCT07787260 protocol and results modules
registry, as of 2025-09-30Stale
https://clinicaltrials.gov/study/NCT06886126
Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus. Overall status RECRUITING. Phases PHASE2. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 240. Conditions Obesity. It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of HDM1005 injection in nondiabetic obese adults.
ClinicalTrials.gov NCT06886126 protocol and results modules
registry, as of 2026-10-01Stale
https://clinicaltrials.gov/study/NCT07828197
A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 135. Conditions Overweight and/or Obesity; Healthy Participants. The purpose of this study is to evaluate the relative bioavailability of a single subcutaneous injection of HDM1005 solution at different injection sites (upper arm and thigh)by using the abdomen subcutaneous injection as a control.
ClinicalTrials.gov NCT07828197 protocol and results modules
registry, as of 2026-08-24Stale
https://clinicaltrials.gov/study/NCT06637020
Phase Ib Clinical Study of HDM1005 Injection. Overall status COMPLETED. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 80. Conditions Overweight and Obesity. This study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation study in overweight or obese subjects to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HDM1005 injection in overweight or obese subj
ClinicalTrials.gov NCT06637020 protocol and results modules
registry, as of 2025-12-16Stale
https://clinicaltrials.gov/study/NCT06640647
Phase Ia Clinical Study of HDM1005 Injection. Overall status COMPLETED. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 65. Conditions Obesity and Overweight. This is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase Ia clinical study. It is aimed to evaluate the safety, tolerability, PK and PD characteristics of HDM1005 injection in healthy adult subjects.
ClinicalTrials.gov NCT06640647 protocol and results modules
registry, as of 2026-03-30Stale
https://clinicaltrials.gov/study/NCT07502001
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin. Overall status NOT_YET_RECRUITING. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 42. Conditions Overweight; Obesity. The purpose of this study is to characterize the Influence of HDM1005 on gastric emptying and drug-drug interaction of HDM1005 and metformin, atorvastatin, warfarin, and digoxin in overweight/obese adult subjects.
ClinicalTrials.gov NCT07502001 protocol and results modules
publication, as of 2026-07-16Stale
https://pubmed.ncbi.nlm.nih.gov/42125916/
Dual Agonist by Molecular Dynamics Evolution. HDM1005 ( poterepatide ), a novel highly potent GLP-1/GIP dual agonist, was engineered via computational alanine scanning and rational acylation design. Nonacylated HDM1005 ( P001 ) showed stable receptor binding and higher affinity than nonacylated
PMID 42125916